Feb 2 2010
“The preparation for a new-drug application for KW-2246 in
Japan is one of the important steps in the international development of
Orexo’s sublingual fentanyl product, in Europe launched under the brand
AbstralTM. This agreement further strengthens the commitment we see from
our partner Kyowa Hakko Kirin in the Japanese market.”
Orexo AB (STO:ORX) announces today that its partner Kyowa Hakko Kirin
Co., Ltd. has entered a joint distribution agreement for the cancer pain
drug KW-2246 (Orexo’s sublingual fentanyl product) with the
pharmaceutical company Hisamitsu Pharmaceutical Co., Inc.
Kyowa Hakko Kirin is responsible for the approval process for the
product in Japan and under the terms of the agreement, KW-2246 will be
jointly distributed by the two companies once the manufacturing and
sales approval is obtained. Each company will carry out independent
product distribution and information provision/gathering activities
under a one-brand, two-channel setup.
Commenting on the announcement, Torbjörn Bjerke, Orexo’s President and
CEO, said: “The preparation for a new-drug application for KW-2246 in
Japan is one of the important steps in the international development of
Orexo’s sublingual fentanyl product, in Europe launched under the brand
AbstralTM. This agreement further strengthens the commitment we see from
our partner Kyowa Hakko Kirin in the Japanese market.”
SOURCE Orexo AB